Kamada director reports 30,000 options at $5.88

Q: What option exercise prices did KMDA director Lilach Asher-Topilsky report?

The reported option entries cover 26,500 ordinary shares at a $7.29 exercise price, 30,000 at $5.88, and 30,000 at $7.26. The exercise prices were adjusted in connection with a special cash dividend declared August 17, 2026. No Rule 10b5-1 plan is reported.

Q: How do the options reported by KMDA director Lilach Asher-Topilsky vest?

The options vest over four years in four equal installments, with 25% vesting on each anniversary of the grant date. They are exercisable for 10 years following the grant date, after which unexercised options expire immediately.

Each option vests in four equal annual installments and is exercisable for 10 years after its grant date.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

KAMADA LTD director Lilach Asher-Topilsky reported three indirect employee stock-option entries held by a trustee under the company's 2011 Share Award Plan. The options cover 26,500 ordinary shares at a $7.29 exercise price, 30,000 at $5.88 and 30,000 at $7.26; the exercise prices were adjusted in connection with a special cash dividend declared August 17, 2026, with a record date of August 27, 2026. The options vest in four equal installments of 25% on each grant-date anniversary and are exercisable for 10 years after grant.

Insider Trade Summary

Grant/Award: 86,500 shares

Grant/Award 3 txns

Insider Asher-Topilsky Lilach

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy) ^{F1, F4, F2, F3}	26,500	$0.00	$0.00
Grant/Award	Employee Stock Option (right to buy) ^{F1, F5, F2, F3}	30,000	$0.00	$0.00
Grant/Award	Employee Stock Option (right to buy) ^{F1, F6, F2, F3}	30,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 86,500 contracts (Indirect, Held by trustee)

Footnotes (6)

F1. The exercise prices of all options reported in this Form 4 are denominated in New Israeli Shekels (NIS). For presentation purposes, all exercise prices presented in this Form 4, including those referenced in the footnotes, are presented in U.S. dollars (USD) based on the NIS/USD exchange rate published by the Bank of Israel as of September 29, 2026.
F2. The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter.
F3. Held by trustee under the Company's 2011 Share Award Plan.
F4. This option was previously reported as covering 26,500 ordinary shares at an exercise price of $7.45. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026.
F5. This option was previously reported as covering 30,000 ordinary shares at an exercise price of $6.05. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026.
F6. This option was previously reported as covering 30,000 ordinary shares at an exercise price of $7.42. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026.

Key Figures

Underlying ordinary shares: 26,500 shares Exercise price: $7.29 per share Underlying ordinary shares: 30,000 shares +5 more

8 metrics

Underlying ordinary shares 26,500 shares Employee stock option held by trustee; reported August 27, 2026

Exercise price $7.29 per share Employee stock option held by trustee; adjusted in connection with the special cash dividend

Underlying ordinary shares 30,000 shares Employee stock option held by trustee; reported August 27, 2026

Exercise price $5.88 per share Employee stock option held by trustee; adjusted in connection with the special cash dividend

Underlying ordinary shares 30,000 shares Employee stock option held by trustee; reported August 27, 2026

Exercise price $7.26 per share Employee stock option held by trustee; adjusted in connection with the special cash dividend

Vesting period 4 years Options vest in four equal installments, with 25% on each grant-date anniversary

Exercise period 10 years Following the date of grant

Key Terms

exercise price, vest, 2011 Share Award Plan

3 terms

exercise price financial

"at an exercise price of $7.45"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"will vest over a period of four years"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option exercise prices did KMDA director Lilach Asher-Topilsky report?

The reported option entries cover 26,500 ordinary shares at a $7.29 exercise price, 30,000 at $5.88, and 30,000 at $7.26. The exercise prices were adjusted in connection with a special cash dividend declared August 17, 2026. No Rule 10b5-1 plan is reported.

How do the options reported by KMDA director Lilach Asher-Topilsky vest?

The options vest over four years in four equal installments, with 25% vesting on each anniversary of the grant date. They are exercisable for 10 years following the grant date, after which unexercised options expire immediately.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/29/2026 - 09:27 AM Accepted by SEC EDGAR 09/29/2026 - 09:27 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Asher-Topilsky Lilach

(Last)

(First)

(Middle)

94 YIGAL ALON ST., ALON TOWER 2.

(Street)

TEL AVIV

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
KAMADA LTD [ KMDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$7.29⁽¹⁾⁽⁴⁾	08/27/2026		A		26,500		⁽²⁾	⁽²⁾	Ordinary Shares	26,500	$0.00	26,500	I	Held by trustee⁽³⁾
Employee Stock Option (right to buy)	$5.88⁽¹⁾⁽⁵⁾	08/27/2026		A		30,000		⁽²⁾	⁽²⁾	Ordinary Shares	30,000	$0.00	30,000	I	Held by trustee⁽³⁾
Employee Stock Option (right to buy)	$7.26⁽¹⁾⁽⁶⁾	08/27/2026		A		30,000		⁽²⁾	⁽²⁾	Ordinary Shares	30,000	$0.00	30,000	I	Held by trustee⁽³⁾

Explanation of Responses:

1. The exercise prices of all options reported in this Form 4 are denominated in New Israeli Shekels (NIS). For presentation purposes, all exercise prices presented in this Form 4, including those referenced in the footnotes, are presented in U.S. dollars (USD) based on the NIS/USD exchange rate published by the Bank of Israel as of September 29, 2026.

2. The options will vest over a period of four years in four equal installments, such that 25% of the options will vest on each anniversary of the grant date. The options will be exercisable for a period of 10 years following the date of grant, and all unexercised options will expire immediately thereafter.

3. Held by trustee under the Company's 2011 Share Award Plan.

4. This option was previously reported as covering 26,500 ordinary shares at an exercise price of $7.45. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026.

5. This option was previously reported as covering 30,000 ordinary shares at an exercise price of $6.05. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026.

6. This option was previously reported as covering 30,000 ordinary shares at an exercise price of $7.42. The exercise price has been adjusted in connection with a special cash dividend distribution declared by the Company's board of directors on August 17, 2026 with a record date for the special cash dividend of August 27, 2026.

	/s/ Lilach Asher Topilsky	09/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR